Pluristem Therapeutics analyst ratings
Pluristem Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/20/2022 | 280.95% | Alliance Global Partners | $9.5 → $4 | Maintains | Buy |
| 05/04/2021 | 1090.48% | Alliance Global Partners | → $12.5 | Initiates Coverage On | → Buy |
| 12/10/2020 | 471.43% | Jefferies | → $6 | Downgrades | Buy → Hold |
| 12/10/2020 | 757.14% | HC Wainwright & Co. | $15.5 → $9 | Maintains | Buy |
| 07/24/2020 | 1423.81% | Jefferies | $12 → $16 | Maintains | Buy |
| 06/19/2020 | 1042.86% | Jefferies | → $12 | Initiates Coverage On | → Buy |
| 12/16/2019 | 1042.86% | Dawson James | → $12 | Initiates Coverage On | → Buy |
| 07/31/2018 | 328.57% | B. Riley Securities | → $4.5 | Initiates Coverage On | → Buy |
| 10/06/2017 | 376.19% | Seaport Global | → $5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/20/2022 | 280.95% | 联盟全球合作伙伴 | 9.5 美元 → 4 美元 | 维护 | 买 |
| 2021 年 4 月 5 日 | 1090.48% | 联盟全球合作伙伴 | → 12.5 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 10 月 12 日 | 471.43% | 杰富瑞集团 | → 6 美元 | 降级 | 买入 → 持有 |
| 2020 年 10 月 12 日 | 757.14% | HC Wainwright & Co. | 15.5 美元 → 9 美元 | 维护 | 买 |
| 07/24/2020 | 1423.81% | 杰富瑞集团 | 12 美元 → 16 美元 | 维护 | 买 |
| 2020 年 6 月 19 日 | 1042.86% | 杰富瑞集团 | → 12 美元 | 启动覆盖范围开启 | → 购买 |
| 2019 年 12 月 16 日 | 1042.86% | 道森·詹姆斯 | → 12 美元 | 启动覆盖范围开启 | → 购买 |
| 07/31/2018 | 328.57% | B. 莱利证券 | → 4.5 美元 | 启动覆盖范围开启 | → 购买 |
| 10/06/2017 | 376.19% | 海港全球 | → 5 美元 | 启动覆盖范围开启 | → 购买 |
Pluristem Therapeutics Questions & Answers
Pluristem Therapeutics 问答
The latest price target for Pluristem Therapeutics (NASDAQ: PSTI) was reported by Alliance Global Partners on July 20, 2022. The analyst firm set a price target for $4.00 expecting PSTI to rise to within 12 months (a possible 280.95% upside). 1 analyst firms have reported ratings in the last year.
联盟全球合作伙伴于2022年7月20日公布了Pluristem Therapeutics（纳斯达克股票代码：PSTI）的最新目标股价。该分析公司将目标股价定为4.00美元，预计PSTI将在12个月内升至12个月内（可能上涨280.95％）。1家分析公司去年公布了评级。
The latest analyst rating for Pluristem Therapeutics (NASDAQ: PSTI) was provided by Alliance Global Partners, and Pluristem Therapeutics maintained their buy rating.
Pluristem Therapeutics（纳斯达克股票代码：PSTI）的最新分析师评级由Alliance Global Partners提供，Pluristem Therapeutics维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pluristem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pluristem Therapeutics was filed on July 20, 2022 so you should expect the next rating to be made available sometime around July 20, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Pluristem Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Pluristem Therapeutics的最新评级是在2022年7月20日公布的，因此您应该预计下一个评级将在2023年7月20日左右公布。
While ratings are subjective and will change, the latest Pluristem Therapeutics (PSTI) rating was a maintained with a price target of $9.50 to $4.00. The current price Pluristem Therapeutics (PSTI) is trading at is $1.05, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Pluristem Therapeutics（PSTI）评级维持不变，目标股价为9.50美元至4.00美元。Pluristem Therapeutics（PSTI）目前的交易价格为1.05美元，超出了分析师的预期区间。